Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib maintenance after chemoradiotherapy in esophageal squamous cell carcinoma
ChiCTR2100054357Phase 2Not yet recruiting
- Sponsor
- Bozhou People's Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Bozhou People's Hospital. Primary endpoints: Progression-free survival and 2-year survival rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100054357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054357.